Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

Next Previous
Trial Profile

Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Oct 2016 Planned End Date changed from 1 Sep 2020 to 1 Oct 2020.
    • 14 Oct 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Oct 2018.
    • 14 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top